A newly developed small-molecule ErbB4 agonist reduces reactive cardiac fibrosis and adverse ventricular remodelling after myocardial infarction in a sex-specific manner.
Event:
ESC Congress 2024
Topic:
Pharmacotherapy
Session:
Heart failure: bench to bedside
/f/125658/7246x3240/f72d1f6fc5/esc-logo-lock-up-red-pos-rgb.png){kind=logo}
/f/125658/3386x1417/951de003e4/hfa-acronym-name-rgb.png)
